Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.

Pharmaceutical firm Sanofi agreed yesterday to acquire UK-based monoclonal antibody therapy developer Kymab in a deal sized at up to $1.45bn that will enable pharmaceutical manufacturer Shenzhen Hepalink to exit. The transaction will consist of $1.1bn in cash and up to $350m in milestone payments. It comes after approximately $220m in funding for the company.…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.